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Introduction
Triple-negative breast cancers (TNBCs) represent about 15-20% of breast cancers, and are characterised by the absence of expression of oestrogen and progesterone receptors and the absence of HER2 overexpression or gene amplification. They show overlapping genomic characteristics with basal BCs [1] [2] [3] . Patients with TNBC have a higher risk of early and visceral relapse than patients with non-TN breast cancer [4] . However, despite recent efforts to find alternative treatments such as hormone therapy and anti-HER2 drugs for, respectively, hormone receptor-positive and HER2-positive breast cancers, there are no efficient targeted therapies for TNBCs and chemotherapy remains the only available systemic treatment [5] . A cell surface protein specifically expressed in TNBC malignant cells and not in normal breast would consequently represent an ideal molecular surface biomarker as well as a potential therapeutic target for antibody-drug conjugate (ADC).
ADCs are monoclonal antibodies conjugated to cytotoxic agents. Antibodies are specific to tumour cell-surface proteins, and thus, have tumour specificity and potency not achievable with traditional drugs [6] . Design of effective ADC for cancer therapy requires the identification of an appropriate target, a monoclonal antibody against the target, potent cytotoxic effector molecules, and conjugation of the monoclonal antibody to cytotoxic agents. Two ADCs recently received approval from the US Food and Drug Administration for treatment of CD30-positive lymphoma (brentuximab-vedotin) and HER2-positive breast cancer (trastuzumab-emtansine), and several new promising ADCs are now in late-phase clinical testing [6, 7] .
PVRL4/Nectin-4 is involved in the formation and maintenance of adherens junctions in cooperation with cadherins [8] [9] [10] . Nectin-4 is a type I transmembrane cell adhesion molecule composed of three Ig-like domains (V-C-C type) in its extracellular region [8] . It is also a receptor for the measles virus, mediating its endocytosis [11] . Nectin-4 is expressed during foetal development, with expression declining in adult life by contrast with the extensive expression of the other nectins in adult tissues [8] . We and others have shown that nectin-4 is re-expressed as a tumourassociated antigen with pro-oncogenic properties in various carcinomas including breast cancer [12] [13] [14] [15] [16] [17] . These features associated with its limited expression in the respective normal tissues, suggest that nectin-4 could be a therapeutic target for ADC in these cancers, as recently reported in bladder, breast and pancreatic cancers [17] .
Here, we have analysed the mRNA and protein expression of nectin-4 in a series of $5700 breast cancers and showed that nectin-4 is a cell surface biomarker more frequently overexpressed in TNBCs and basal breast cancers, and that high mRNA expression is an independent poor-prognosis factor in TNBCs. Then, we have developed an anti-nectin-4 ADC and showed its therapeutic efficiency on localised and metastatic TNBC both in vitro and in vivo, with rapid, complete, and long-lasting regression in nectin-4-positive patient samples.
Materials and methods

Patients and breast cancer samples
The clinical samples had been profiled using DNA microarrays for gene expression analyses. Our own data set included 353 cases representing pre-treatment invasive carcinomas from patients non-metastatic at diagnosis. The study was approved by our institutional review board (IRB agreement no. 15-002). Each patient gave a written informed consent for research use. We pooled our series with 17 publicly available data sets comprising at least one probe set representing PVRL4/nectin-4. These sets were collected from the National Center for Biotechnology Information (NCBI)/Genbank GEO and ArrayExpress databases, and authors' website (supplementary Table S1 , available at Annals of Oncology online). The final pooled set included 5673 non-redundant, non-metastatic, non-inflammatory, primary, invasive breast cancers with PVRL4 mRNA expression and clinicopathological data available (supplementary Table S2 , available at Annals of Oncology online).
For protein expression, we analysed a consecutive series of 61 previously untreated TNBC samples collected at the time of diagnosis from women treated at our Institute. Informed consent was obtained for each patient and the study was approved by our IRB (supplementary Table S3 , available at Annals of Oncology online).
MDA-MB-231 and SUM190 breast cancer cell lines were used in this study. Detailed information is available in supplementary Methods (available at Annals of Oncology online).
Gene expression data analysis
Our own gene expression data set had been generated using Affymetrix U133 Plus 2.0 human microarrays (Affymetrix V R , Santa Clara, CA) as described [18] . MIAME-compliant data are deposited in the GEO database (GSE31448). PVRL4 expression was measured by analysing different probe sets whose identity and specificity were verified using the NCBI program BLASTN 2.2.31þ (supplementary Table S4 
Production of ADC
The ADC was produced by Concortis (San Diego, CA). Conjugates were produced from purified mab1/N41mab monoclonal antibody. The linker used was the maleimidocaproyl-L-valine-L-citrulline-p-aminobenzyl alcohol p-nitrophenyl carbonate (MC-Val-Cit-PAB-PNP) covalently conjugated to monomethyl auristatin-E (MMAE). This cleavable linker was selected because it induced potent bystander killing. The drug-toantibody ratio was 4.73.
Animal models
All experiments were done in agreement with the French Guidelines for animal handling and approved by local ethics committee (Agreement no. 01152-01). Additional details are available in supplementary Methods (available at Annals of Oncology online).
Statistical analysis
This section is detailed in supplementary Methods (available at Annals of Oncology online).
Results
Nectin-4/PVRL4 is expressed in TNBC and predicts poor prognosis
We examined PVRL4 expression in breast cancer. Whole-genome clustering of our 353-sample series showed that PVRL4 mRNA was in the 'basal' gene cluster and more consistently expressed in basal tumours ( Figure 1A and B). We analysed nectin-4 protein expression by immunohistochemistry (IHC) in 61 TNBCs, 12 of them previously profiled using DNA microarrays. The monoclonal antibody used for this analysis, selected from our screening (see next paragraph), recognised the distal IgV-like domain of human nectin-4 and did not cross-react with the other human nectins or with mouse nectin-4 (supplementary Figure S1 , available at Annals of Oncology online). Nectin-4 expression was detected at the plasma membrane. Based on the QuickScore (QS) semiquantitative assessment, we distinguished a 'nectin-4-high group' (QS > 100) and a 'nectin-4-low group' (QS 100), representing 62% and 38% of TNBCs, respectively ( Figure 1C ). There was a positive correlation between mRNA and protein expression of nectin-4 (supplementary Figure S2 , available at Annals of Oncology online; P ¼ 0.002). Importantly, nectin-4 was detected neither in the normal mammary gland epithelium ( Figure 1D Figure S3, available at Annals of Oncology online) [10] . These results established nectin-4 as both a new cell surface biomarker and a potential target for TNBCs. We then analysed a pooled series of 5673 invasive breast cancers profiled using DNA microarrays and five different PVRL4 probes 100% specific. High PVRL4 expression was associated with poor-prognosis features, including both TN and basal subtypes (supplementary Table S5 , available at Annals of Oncology online). PVRL4 was highly expressed in 61% of TN samples and 62% of basal samples versus 47% of non-TN or non-basal samples. Metastasis-free survival (MFS) data were available for 1037 patients, including 613 without metastatic relapse (median follow-up, 83 months) and 424 with metastatic relapse (median time to relapse, 24 months). The 5-year MFS rate was 61% (95 %CI, 0.58-0.65). In the whole population, high PVRL4 expression was associated with shorter MFS (P ¼ 0.014, log-rank test) (supplementary Figure S4 , available at Annals of Oncology online). Prognostic univariate analysis per molecular subtype showed that high PVRL4 expression was associated with MFS in the TN subtype only, with 5-year MFS of 47% (95%CI, 0.40-0. 55) versus 62% (95%CI, 0.51-0.74) in the 'PVRL4-high' and 'PVRL4-low' groups, respectively (P ¼ 0.014, log-rank test) ( Figure 1E ). In multivariate analysis (Table 1) , high PVRL4 expression remained significant (P ¼ 0.039, Wald test; HR ¼ 1.53 [1.02-2.30]). Altogether, these results indicated that PVRL4/ nectin-4 is commonly expressed in TN or basal breast cancers, not expressed in the normal breast, and is an independent predictor of shorter MFS in TNBCs.
ADC-based targeting of nectin-4 in vitro
We tested six monoclonal antibodies (mAbs) directed against the IgV-like distal domain of nectin-4 to isolate a mAb able to induce internalisation. MAbs were evaluated for EC50, maximum binding capacity, cell surface internalisation and cytotoxicity (supplementary Figure S5 , available at Annals of Oncology online). Internalisation was tested using ectopically expressed Flag-tagged nectin-4 expressed in MDA-MB-231 cells and FITC-labelled anti-Flag antibody (M2, Sigma-Aldrich, St. Louis, MO) to quantify residual surface nectin-4. Mab1 was the most efficient antibody. It induced a 60% decrease of cell surface nectin-4 in 24 h and a 60% cell growth inhibition after incubation with a goat anti-mouse monoclonal antibody conjugated to saporin (mab-ZAP kit, ATS-bio, San Diego, CA). Internalisation and cytotoxicity were positively correlated (R 2 ¼ 0.96). Mab1 did not affect cell viability in vitro and tumour cell growth in vivo (data not shown). Mab1 was then conjugated to monomethyl auristatin-E (MMAE) via a cleavable valine-citrulline (vc) di-peptide linker (thereafter called N41mab-vcMMAE, ADC) to produce an ADC, which was then tested in vitro for specificity and efficacy on selected breast cancer cell lines. MDA-MB-231 cells, which express nectin-1, nectin-2, and nectin-3, but not nectin-4, were not sensitive to the ADC. However, ectopic expression of nectin-4 conferred sensitivity with an IC50 ¼ 2 ng/ml (supplementary Figure S6A , available at Annals of Oncology online). SUM190 cells, which express endogenous nectin-4, were sensitive with an IC50 ¼ 4 ng/ml (supplementary Figure S6B , available at Annals of Oncology online). These data showed the specificity and the efficacy of N41mab-vcMMAE.
ADC-based targeting of nectin-4 in vivo
Activity of our ADC was tested in three in vivo models of TNBC developed in immunocompromised NSG mice. First, mice xenografted with SUM190 cells were treated with two successive i.v. doses of N41mab-vcMMAE (Figure 2A ). These doses were not toxic for mice (supplementary Figure S7 , available at Annals of Oncology online). N41mab-vcMMAE induced a rapid (4 days) and complete tumour regression, the duration of which was dose-dependent and lasted up to 40 days at the 10 mg/kg dose ( Figure 2A) . Interestingly, after relapse, tumours still kept their sensitivity to the ADC with tumour regression similar to that obtained after the first treatment, at least over a 6-months period ( Figure 2B) .
Second, we used patient-derived xenografts (PDX) of nine primary TNBCs. These pre-clinical models recapitulate breast cancer physiopathology [19] . Localisation and levels of nectin-4 expression in PDX were similar to that found in TNBC patients (supplementary Figure S8 , available at Annals of Oncology online). Nectin-4 expression was prominently found at the plasma membrane in seven of nine PDX (QS > 100). TNBC PDX mice Figure 2F ). In contrast, treatment of PDX 348-sensitive to our ADC-by docetaxel (3 times 10 mg/kg i.p.) was ineffective ( Figure 2G ). Third, to evaluate ADC treatment efficacy in a more advanced disease, we treated PDX400 and PDX317 mice developing spontaneous metastatic lesions from primary tumours. In both cases, treatment with two successive i.v. doses of ADC led to a rapid reduction and complete disappearance of all metastatic lesions observed by luminescence analysis (Figure 3) . Metastatic recurrences were detected at days 42 and 57 for PDX400, and still not observed for PDX317 (ongoing experiment: day 245) (data not shown). These results showed that N4mab1-vcMMAE had a marked anti-tumour activity in both primary and metastatic nectin-4-expressing TNBCs.
Discussion
Nectin-4 has been reported as a new tumour antigen for different carcinomas [12] [13] [14] [15] [16] [17] . Here, we have analysed its mRNA and protein expression in a series of $5700 breast cancers and showed that nectin-4 is a cell surface biomarker more frequently overexpressed in TNBCs and basal breast cancers, and that high mRNA expression is an independent poor-prognosis factor for MFS in TNBCs. Then, we developed an anti-nectin-4 ADC and showed its therapeutical efficiency on localised and metastatic TNBC both in vitro and in vivo, with rapid and long-lasting regression in nectin-4-positive samples. To our knowledge, this work is the first description of a cell surface biomarker eligible for the systemic treatment of TNBCs.
We showed that nectin-4 is a cell surface biomarker more frequently overexpressed in TNBCs and basal breast cancers. Its protein expression, analysed by IHC using our antibody, was detected at the plasma membrane and positively correlated with mRNA expression. High-protein expression and high mRNA expression were found in the same proportion of cases, nearly two-thirds of TNBCs. This protein expression pattern was confirmed using four other monoclonal antibodies recognising different epitopes in the nectin-4 ectodomain (supplementary Figure S9 , available at Annals of Oncology online). Importantly, nectin-4 protein was not detected in the normal mammary gland epithelium and 30 other different adult normal tissues except the skin. These results confirmed and extended our previous work done within a limited number of samples [12] (Figure 1 ). To our knowledge, nectin-4 expression has been studied in clinical breast cancer samples in three other studies using IHC in two series of 197 [20] and 654 [17] cases and using IHC in a series of imprint smears of 140 cases [21] . Two studies used the same commercial polyclonal antibody [20, 21] . We tested this antibody on nectin-4 mRNA negative TNBCs and found a cytoplasmic and a nuclear staining by IHC (data not shown). This polyclonal antibody recognised nectin-4 by western-blot but, in contrast to N41mab, gave a high background signal on nectin-4 mRNA negative MDA-MB-231 cells (supplementary Figure 1B , available at Annals of Oncology online). In the third study, authors generated their own monoclonal antibody, directed against the extra-cellular domain of human nectin-4, and analysed 654 breast cancers (primary tumours and metastases): 53% of specimens showed moderate to strong staining, but no correlation with clinicopathological features or survival was looked for. In our series, high nectin-4 expression was an independent poor-prognosis factor for MFS in the TNBC patients only. Interestingly, we observed that nectin-4 overexpression increased tumour growth and metastasis formation in mouse xenograft models (data not shown). De novo expression of nectin-4 may perturb nectin-supported adherens junctions and increase cell migration. Nectin-4 presents two interesting properties: an inducible and efficient internalisation, which is hijacked by the measles virus, and a limited expression in healthy tissues. Together, these properties make nectin-4 an attractive target for the development of immune-base therapies especially for TNBCs for which no specific cell surface antigen has been identified so far [22] . ADC directed against nectin-4 has been recently shown efficient in mice models subcutaneously xenografted with cell lines [17] . Based on in vitro assessment of EC50, maximum binding capacity, cell surface internalisation and cytotoxicity, we retained the Mab1 for ADC approach. Mab1 was then conjugated to monomethyl auristatin-E (MMAE) via a cleavable linker to produce an ADC, thereafter called N41mab-vcMMAE. This ADC was validated in vitro for efficiency and specificity.
We then showed its in vivo activity in models of TNBC developed in immunocompromised NSG mice. The model based on the SUM190 cell line exhibited rapid and complete response, the duration of which was prolonged and dependent on the dose; furthermore, the relapses remained similarly sensitive to our ADC over the 6-months period tested. We also took advantage of our collection of primary TNBC PDXs phenotypically close to the physiopathology of TNBCs [19] . In these models, patient tumours develop in the mouse mammary gland and spontaneously spread to the same sites as do metastatic TNBCs (Figure 3 ). High expression of nectin-4 was found in two-thirds of PDXs, a proportion close to that observed in our clinical series. The results showed a marked efficiency of the anti-nectin-4 ADC with complete and durable eradication of both localised TNBC tumours and metastatic lesions of different sites. These data not only confirmed the results previously reported [17] with another antinectin-4 ADC (AGS-22M6E) but also showed additional important results. Our ADC induced complete and durable responses on both primary tumours, metastatic lesions and local relapses, and the degree of response was dependent on the nectin-4 tumour expression level. We surmise that tumour shrinkage is due to toxin delivery because N41mab without drug did not have intrinsic anti-tumour growth activity both in vitro and in vivo. In vivo pre-clinical responses with N41mab-vcMMAE were observed for 'nectin-4-high' TN tumours (QS > 100), predicting a good response in most TNBC patients (62% of cases). We also found similar efficacy between N41mab conjugated to emtansine (N41mab-DM1) and trastuzumab-DM1 [23] in SUM190-xenografted mice (data not shown). Because both nectin-4 and HER2 are equally expressed at the surface of SUM190 cells, we can postulate that nectin-4-based ADC is at least as efficient as trastuzumab-DM1 in this model. Efficacy of drugs used for treatment in humans is closely dependent on the toxicity they induce in healthy tissues. This is also true for ADC-based therapy where expression of the target has to be restricted to the malignant cells. Consequently, the restricted expression pattern of nectin-4 in humans would predict a limited toxicity. The ADC tested here did not induce any toxicity in mice even after repeated treatments. However, this cannot predict an absence of toxicity in humans because our N41mab does not cross-react with murine nectin-4. A phase I study addressing this issue was recently completed for examining the safety of AGS-22M6E ADC as monotherapy in patients with malignant solid tumours expressing nectin-4 (Clinical Trials.gov Identifier, NCT01409135). Another ongoing phase I study is assessing the safety and pharmacokinetics of escalating doses of ASG-22CE given as monotherapy in subjects with metastatic urothelial cancer and other malignant solid tumours that express nectin-4 (Clinical Trials.gov Identifier, NCT02091999).
In conclusion, we show that nectin-4 is a new promising therapeutic target in the armamentarium against TNBC. It is a cell surface biomarker frequently expressed in TNBCs, with independent negative prognostic value, and without expression in normal breast tissue. The anti-nectin 4 ADC that we developed (N41mab-vcMMAE) induced complete and durable responses in vitro and in vivo on nectin-4-positive samples including primary tumours, metastatic lesions and local relapses; efficiency was dependent on both the dose and the nectin-4 tumour expression level. Evaluation of this ADC in the clinical setting is warranted. Additionally, because resistance to auristatin-based ADC has been reported [24] , we are currently developing in vivo models aiming to evaluate tumour resistance to our ADC.
